Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zedenoleucel by Marker Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
Zedenoleucel is under clinical development by Marker Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
Zedenoleucel by Marker Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Zedenoleucel is under clinical development by Marker Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
TPIV-110 by Marker Therapeutics for Ductal Carcinoma In Situ: Likelihood of Approval
TPIV-110 is under clinical development by Marker Therapeutics and currently in Phase I for Ductal Carcinoma In Situ. According to...
Neldaleucel by Marker Therapeutics for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Neldaleucel is under clinical development by Marker Therapeutics and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to...
Neldaleucel by Marker Therapeutics for CNS Lymphoma: Likelihood of Approval
Neldaleucel is under clinical development by Marker Therapeutics and currently in Phase I for CNS Lymphoma. According to GlobalData, Phase...